Thanks to AIRC funding we have the opportunity to implement our research in the cancer field and to recruit two researchers in our group

We have recently received wonderful news: one of the funding requests has gone through! Indeed, an AIRC grant will allow us to implement our research on cancer, in parallel to ongoing studies in the field of cardiac regeneration and cardiotoxicity of anticancer therapies.

In fact, our laboratory aims at understanding the molecular mechanisms underlying cell differentiation and proliferation to develop new strategies to “block” cancer cells and to “unlock” the cardiac regenerative potential. In particular, with this project, we aim at studying the deregulations responsible for the development and progression of basal-like breast cancer, an aggressive tumor subtype.

In this research project, we will analyze the role and the molecular mechanisms activated by growth factors in cell differentiation. We hypothesize that pushing basal breast cancer cells towards a more differentiated phenotype would reduce their aggressiveness. The project has the potential to develop new differentiation strategies to prevent primary tumor cells from disseminating throughout the body and creating the so-called metastases, one of the major problems in solid tumor progression.

This funding will give us the opportunity to recruit two researchers (postgraduate or postdoc) in our research group in Bologna, from February / March 2021 for a total of five-year. Pre-doctoral researchers may also have the opportunity to start a PhD track. Interested and motivated researchers can contact us by email (duva.gabriele@gmail.com), attaching their CV.

Fellowship opportunity in our lab

We are recruiting a research fellow at MultiMedica ONLUS Foundation (Milan). The contract is for 1 year, starting from June 2018, and potentially renewable for a total of three years.
The project is funded by Cariplo Foundation and the research will be conducted in our laboratory, which forms a bridge between the fields of cancer, cardiotoxicity of anticancer therapies and cardiac regeneration.

The selected research fellow will develop a project on the cardiotoxicity of anti-cancer therapies. Cardio-toxicity is a common side effect of chemotherapy and targeted anti-cancer therapies, strongly impacting on the quality of life and the overall survival, regardless of the oncological prognosis. The goal is to develop strategies for reducing the cardiotoxic side effects of current anti-cancer therapies, while simultaneously improving their efficacy. By employing both breast cancer cells and primary mouse cardiomyocytes cultures in vitro, the research activities will be focused on the role of specific growth factors and receptors on cell differentiation status, and the impact on tumour growth and cardiotoxic side effects. In vivo analysis on mouse models will also be conducted.

Applicants requirements: Applicants must have a molecular-, cell- and biochemistry backgrounds, such as a Master Degree in Biotechnology, Biology or related field. Candidates must have at least one year of experience in a research laboratory. Familiarity with standard molecular biology techniques (Real Time PCR, Western Blot, Immunofluorescence analysis…), as well as the expertise in cardiac and/or tumour biology, are required. Passion for science as well as a positive attitude towards solving problems is required in order to pursue technically challenging and intellectually stimulating projects in the lab.

Other criteria: PhD Degree is not required, but is positively evaluated. Expertise in procedures for the induction of cardiac damage (by cardiotoxic drugs or myocardial infarction) as well as in the analysis of microarray o RNA-seq datasets is a plus factor for the selection process.

How to apply: Applicants should send their CV by email with subject line “Research fellowships at Fondazione MultiMedica ONLUS” to Dr. Gabriele D’Uva (gabriele.duva@multimedica.it). One or more letters of recommendation are welcome, although not strictly required. Interviews will be conducted for selected candidates until the position is filled.

Previous publications relevant to the project:
• D’Uva G et al., ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation. Nature Cell Biology, 2015
• D’Uva G and Tzahor E, The key roles of ERBB2 in cardiac regeneration. Cell Cycle. 2015
• Yutzey KE. Regenerative biology: Neuregulin 1 makes heart muscle. Nature, 2015 (News & Views on our article)
• D’Uva G and Lauriola M, Towards the emerging cross-talk: ERBB family and steroid hormones. Seminars in Cell and Developmental Biology, 2016